3-(2-Methylaminoethyl)indol-5-ol oxalate,
15558-50-6,
1975-81-1,
N-omega-Methyl-5-hydroxytryptamine oxalate salt,
N-omega-Methylserotonin,
MFCD00013159,
H-7000,
Nomega-Methyl-5-hydroxy-trypt-amine oxalate salt,
NSC91541,
EINECS 239-611-4,
5-hydroxy-nw-methyltryptamine oxalate,
AC1Q5RMG,
N-Methylserotonin oxalate,
MLS000859941,
SCHEMBL1320479,
CHEMBL1256286,
CTK0I2793,
N|O-Methylserotonin oxalate salt,
DTXSID80293695,
HMS2234N19,
HMS3262E08,
HMS3371J12,
Nomega-Methylserotonin oxalate salt,
AC1L6327,
Tox21_500743,
NSC-91541,
AKOS024282337,
5-Hydroxy-N|O-methyltryptamine oxalate,
ACM1975811,
CCG-222047,
LP00743,
MCULE-1823155663,
N-omega-METHYL-5-HYDROXYTRYPTAMINE,
NCGC00094085-01,
NCGC00261428-01,
5-Hydroxy-Nomega-methyltryptamine oxalate,
SMR000326801,
ST055634,
EU-0100743,
FT-0620492,
M 1514,
N|O-Methyl-5-hydroxy-trypt-amine oxalate salt,
5-Hydroxy-N-omega-methyltryptamine, oxalate salt,
5-Hydroxy-Nomega-methyltryptamine oxalate, 99%,
3-(2-(Methylamino)ethyl)-1H-indol-5-ol oxalate,
Nomega'-Methyl-5-hydroxy trypt amine oxalate salt,
SR-01000075980,
J-012764,
SR-01000075980-1,
3-[2-(methylamino)ethyl]indol-5-ol, ethanedioic acid,
3-[2-(methylamino)ethyl]-1H-indol-5-ol; oxalic acid,
1H-Indol-5-ol, 3-[2-(methylamino)ethyl]-, ethanedioate (1:),
3-(2-Methylaminoethyl)indol-5-ol oxalate, N-Methylserotonin oxalate,
Nomega-Methyl-5-hydroxy??trypt??amine oxalate salt, >=98% (alkalimetric),
C11H14N2O.xC2H2O4,
5-Hydroxy-N-methyltryptamine oxalate,
AR-1G8550,
CID260390,
C11-H14-N2-O.x-C2-H2-O4,
19831-78-8,